GI INNOVATION, INC. |
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
| 12,280 KRW | -1.21% |
|
-9.77% | +1.91% |
| 2023 | GI Innovation, Inc.(KOSDAQ:A358570) added to S&P Global BMI Index | CI |
| 2023 | GI Innovation, Inc. has completed an IPO in the amount of KRW 26 billion. | CI |
| 1 day | -1.21% | ||
| 1 week | -9.77% | ||
| Current month | -6.54% | ||
| 1 month | -4.81% | ||
| 3 months | +9.74% | ||
| 6 months | +23.42% | ||
| Current year | +1.91% |
1 week
11 760.00
14 000.00
1 month
11 760.0014 000.00
Current year
9 810.0014 650.00
1 year
8 080.0015 700.00
3 years
8 080.0015 700.00
5 years
8 080.0015 700.00
10 years
8 080.0015 700.00
| Managers | Title | Age | Since |
|---|---|---|---|
Jun-Ho Hong
CEO | Chief Executive Officer | 52 | - |
Byeong-Geon Lee
CEO | Chief Executive Officer | 67 | 22-03-03 |
Jin-Man Kim
DFI | Director of Finance/CFO | 42 | 17-08-31 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Byeong-Geon Lee
CEO | Chief Executive Officer | 67 | 22-03-03 |
Su-Yeon Nam
PSD | President | 58 | 18-11-30 |
Geun-Yong An
BRD | Director/Board Member | 49 | 22-02-28 |
GI Innovation Inc is a Korea-based company engaged in the research and development of next-generation immunotherapies based on fusion proteins. The Company is engaged in the business of generating revenue through license fees by technology transfer of new drug candidates in pre-clinical and early clinical stages. The core new drug pipeline includes products such as GI-101 immuno-oncology and GI-301 allergy treatment.
Calendar
2024-08-11
- Q2 2024 Earnings Release (Projected)
Annual profits - Rate of surprise
| 1st Jan change | Capi. | |
|---|---|---|
| +1.91% | 403M | |
| +50.97% | 63.85B | |
| -2.41% | 41.83B | |
| +40.01% | 40.47B | |
| -10.22% | 27.17B | |
| +13.48% | 26.52B | |
| -20.65% | 18.69B | |
| +2.81% | 12.73B | |
| +22.22% | 12.11B | |
| +27.76% | 12.07B |
- Stock Market
- Equities
- A358570 Stock
